Mualliflar

  • Хамраев Б.Ж., Хамидова Ф.М.

##semicolon##

муковисцидоз, CFTR, бронхоэктазия, дети, морфология, молекулярно-генетическая диагностика, реактивные изменения.

##submission.citations##

1. Mehdizadeh Hakkak A., Keramatipour M., Talebi S., Brook A., Tavakol Afshari J., Raazi A. Molecular analysis of the CFTR gene in Iranian cystic fibrosis patients // Iranian Journal of Basic Medical Sciences.

— 2013. — Vol. 16, № 8. — P. 917–921.

2. Boboniyazov I., Khamidova F.M., Khamraev B.J. Modern aspects of molecular genetic diagnosis of cystic fibrosis in children // Journal of Biomedicine and Practice. — 2024. — Vol. 9, № 2. — P. 45–51.

3. Эседов Э.М., Кондратьева Е.И., Шерман В.Д. Муковисцидоз у детей: современные представления о патогенезе, диагностике и лечении // Педиатрия. — 2016. — Т. 95, № 4. — С. 112–118.

4. Ratjen F., Bell S.C., Rowe S.M., Goss C.H., Quittner A.L., Bush A. Cystic fibrosis // Nature Reviews Disease Primers. — 2015. — Vol. 1. — Article ID 15010.

5. Elborn J.S. Cystic fibrosis // The Lancet. — 2016. — Vol. 388, № 10059. — P. 2519–2531.

6. Mall M.A., Hartl D. CFTR: cystic fibrosis and beyond // European Respiratory Journal. — 2014. — Vol. 44, № 4. — P. 1042–1054.

7. Stoltz D.A., Meyerholz D.K., Welsh M.J. Origins of cystic fibrosis lung disease // New England Journal of Medicine. — 2015. — Vol. 372, № 4. — P. 351–362.

8. Boucher R.C. Muco-obstructive lung diseases // New England Journal of Medicine. — 2019. — Vol. 380,

№ 20. — P. 1941–1953.

9. Cantin A.M., Hartl D., Konstan M.W., Chmiel J.F. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy // Journal of Cystic Fibrosis. — 2015. — Vol. 14, № 4. — P. 419–430.

10. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis // American Journal of Respiratory and Critical Care Medicine. — 2003. — Vol. 168, № 8. — P. 918–951.

11. Полшведкина О.Б., Скачкова М.А., Кондратьева Е.И. Клинические особенности бронхолёгочного поражения при муковисцидозе у детей // Российский педиатрический журнал. — 2017. — Т. 20, № 5. — С. 276–281.

12. Flume P.A., Mogayzel P.J., Robinson K.A., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations // American Journal of Respiratory and Critical Care Medicine. — 2009. — Vol. 180, № 9. — P. 802–808.

13. Regamey N., Jeffery P.K., Alton E.W., et al. Airway remodelling and its relationship to inflammation in cystic fibrosis // Thorax. — 2011. — Vol. 66, № 7. — P. 624–629.

14. Hays S.R., Fahy J.V. Characterizing mucous cell remodeling in cystic fibrosis // American Journal of Respiratory and Critical Care Medicine. — 2006. — Vol. 174, № 9. — P. 1018–1024.

15. Kapur N., Masters I.B., Chang A.B. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis // Chest. — 2010. — Vol. 138, № 1. — P. 158–164.

16. Chalmers J.D., Chang A.B., Chotirmall S.H., Dhar R., McShane P.J. Bronchiectasis // Nature Reviews Disease Primers. — 2018. — Vol. 4. — Article ID 45.

17. Pier G.B., Grout M., Zaidi T.S. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung // Proceedings of the National Academy of Sciences USA. — 1997. — Vol. 94, № 22. — P. 12088–12093.

18. Darling K.E.A., Evans T.J. Effects of Pseudomonas aeruginosa infection on cystic fibrosis airway inflammation // Future Microbiology. — 2017. — Vol. 12, № 12. — P. 1067–1079.

19. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome // Nature Medicine. — 2012.

— Vol. 18, № 4. — P. 509–519.

20. Chang A.B., Bush A., Grimwood K. Bronchiectasis in children: diagnosis and treatment // The Lancet. — 2018. — Vol. 392, № 10150. — P. 866–879.

21. Pasteur M.C., Bilton D., Hill A.T. British Thoracic Society guideline for non-CF bronchiectasis // Thorax.

— 2010. — Vol. 65, Suppl. 1. — P. i1–i58.

22. Cutting G.R. Cystic fibrosis genetics: from molecular understanding to clinical application // Nature Reviews Genetics. — 2015. — Vol. 16, № 1. — P. 45–56.

23. Castellani C., Cuppens H., Macek M. Jr., et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice // Journal of Cystic Fibrosis. — 2008. — Vol. 7, № 3. — P. 179– 196.

24. McGarry M.E., McColley S.A. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype // Pediatric Pulmonology. — 2021. — Vol. 56, № 6. — P. 1496–1503.

25. Баратаева М.Б., Рахмонова А.А. Клинические и диагностические особенности муковисцидоза у новорождённых в Узбекистане // Вестник врача. — 2024. — № 2. — С. 38–43.

26. Farrell P.M., White T.B., Ren C.L., et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation // Journal of Pediatrics. — 2017. — Vol. 181S. — P. S4–S15.

27. De Boeck K., Amaral M.D. Progress in therapies for cystic fibrosis // The Lancet Respiratory Medicine.

— 2016. — Vol. 4, № 8. — P. 662–674.

28. Кондратьева Е.И., Красовский С.А., Амелина Е.Л., Шерман В.Д. Муковисцидоз: клинические рекомендации, диагностика и лечение. — Москва: Медпрактика-М, 2021. — 160 с.